KR20130081131A - Composition and health liquor containing the extract of dandelion, siberian-ginseng, red ginseng, cherokee rose, mugwort and ginkgo leaf - Google Patents
Composition and health liquor containing the extract of dandelion, siberian-ginseng, red ginseng, cherokee rose, mugwort and ginkgo leaf Download PDFInfo
- Publication number
- KR20130081131A KR20130081131A KR1020120002130A KR20120002130A KR20130081131A KR 20130081131 A KR20130081131 A KR 20130081131A KR 1020120002130 A KR1020120002130 A KR 1020120002130A KR 20120002130 A KR20120002130 A KR 20120002130A KR 20130081131 A KR20130081131 A KR 20130081131A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- ethanol
- red ginseng
- hair loss
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 민들레 추출물, 가시오가피 추출물, 홍삼 추출물, 금앵자 추출물, 애엽 추출물 또는 은행잎 추출물 첨가된 조성물 및 건강주에 관한 것으로, 구체적으로는 테스토스테론 5알파-리덕타아제(testosterone 5α-reductase)를 저해함으로써 탈모와 전립선 비대증을 예방할 수 있는 조성물 및 건강주에 관한 것이다.The present invention relates to dandelion extract, prickly pear extract, red ginseng extract, golden primrose extract, leaf extract or ginkgo biloba extract added composition and healthy liquor, specifically by inhibiting testosterone 5α-reductase (testosterone 5α-reductase) The present invention relates to compositions and healthy strains capable of preventing hair loss and enlarged prostate.
현대 사회에 들어 각종 스트레스, 환경오염, 약물 오남용 등으로 인한 부작용, 파마, 염색, 정발제류의 사용 및 유전적인 요인 등으로 인해 탈모의 발생이 더욱 심각해짐에 따라 발모 또는 육모 대한 관심이 증가 되고 있다.In modern society, as the occurrence of hair loss becomes more serious due to side effects due to various stresses, environmental pollution, drug abuse, perm, dyeing, use of hair dressings, and genetic factors, there is increasing interest in hair growth or hair growth. .
탈모의 원인으로는 혈액순환 불량설, 남성호르몬 작용 과잉설, 피지 분비 과잉설, 비듬균 및 기타세균 등에 의한 두피기능 저하설, 유전적 요인, 노화 스트레스 등이 제시되어 왔으나, 현재까지 탈모에 관한 명확한 원인은 밝혀져 있지 않다. 또한, 최근 들어 식생활의 변화, 사회 환경 등에 의한 스트레스의 증가 등으로 탈모로 고민하는 인구가 늘어나고 있는 추세이다.The causes of hair loss include poor blood circulation, excessive male hormone action, excessive sebum secretion, deterioration of scalp function by dandruff and other bacteria, genetic factors, aging stress, etc. The cause is unknown. Also, in recent years, the number of people who suffer from hair loss due to changes in diet, increase of stress due to social environment, etc. is increasing.
탈모증의 원인 중 남성호르몬 과잉 분비와 직접적인 관계가 있는 것으로, 통상 남성형 탈모증(male pattern baldness)이라고 불리는 안드로겐성 탈모증(androgenic alopecia)이 있다. 안드로겐성 탈모증이 있는 경우, 건강한 모발은 점차로 가늘어지고, 짧아지며, 모발이 약해져서 쉽게 부서지는 현상이 나타나게 되는데, 이러한 현상을 축소화(miniaturization)라고 한다. 축소화가 일어나는 모낭은 가늘고 눈에 잘 보이지 않으며, 짧은 솜털로 변해 결국 탈모가 진행되는 것이다. 이에 따라 최근 남성호르몬 활성 억제를 통한 탈모의 예방 및 치료를 위한 많은 연구가 보고되고 있다.One of the causes of alopecia is directly related to the excessive release of male hormone, and is called androgenetic alopecia, commonly called male pattern baldness. In the case of androgenetic alopecia, healthy hair gradually becomes thinner, shorter, and weaker, leading to brittleness, which is called miniaturization. The hair follicles, which shrink, become thin and invisible, turn into short hairs and eventually develop hair loss. Accordingly, many studies have recently been reported for the prevention and treatment of hair loss through inhibition of male hormone activity.
남성탈모증은 남성호르몬 중의 하나인 테스토스테론(testosterone)이 테스토스테론 5알파-리덕타아제(testosterone 5a-reductase)에 의해 활성형 남성호르몬인 디히드로테스토스테론(dihydrotestosterone, DHT)으로 전환되고, 이렇게 활성화된 디히드로테스토스테론이 안드로겐 수용체와 결합하여 모낭세포의 단백질 합성을 지연시켜 모낭의 생장기가 단축되고 모낭을 위축시킴으로써 유발된다. 또한, 안드로겐성 탈모 과정에서 피지가 과잉 생성되어 염증을 동반한 탈모가 나타나기도 한다.In male alopecia, testosterone, one of the male hormones, is converted by testosterone 5a-reductase to dihydrotestosterone (DHT), an active male hormone. Testosterone binds to androgen receptors to delay protein synthesis in hair follicle cells, resulting in shorter hair follicle growth and atrophy of hair follicles. In addition, in the process of androgenetic alopecia, sebum is excessively produced, resulting in hair loss with inflammation.
한편, 과도한 디히드로테스토스테론에 의해 유발되는 질환 중 하나로 양성전립선 비대증이 있다. 전립선 비대증은 과거에는 전립선이 비대해져 방광 하부의 소변이 나오는 통로를 막아 요도 폐색을 일으켜 소변의 흐름이 감소된 상태로 정의하였고, 조직학적으로는 전립선 간질이나 전립선의 상피조직 세포가 증식된 것으로 정의하였다. On the other hand, one of the diseases caused by excessive dehydrotestosterone is benign prostatic hyperplasia. In the past, prostatic hyperplasia was defined as a condition in which the prostate was enlarged to block the passage of urine in the lower bladder, causing urethral obstruction, which reduced the flow of urine, and histologically defined as proliferation of prostate epilepsy or epithelial cells of the prostate. .
하지만, 최근에는 상기와 같은 정의나 개념으로 설명하기에는 질병의 병태 생리가 너무 복잡하여, 현재 '50세 이상의 남성에서 하루 8회 이상 소변을 보는 빈뇨, 야간 빈뇨, 강하고 갑작스런 요의(오줌이 마려운 느낌)를 느끼면서 소변이 마려우면 참을 수 없는 절박뇨 등의 방광 저장 증상과 지연뇨(소변을 볼 때 뜸을 들여야 소변이 나오는 현상), 단절뇨(소변의 흐름이 끊기는 현상), 배뇨 시 힘을 주어야 하는 현상 등 방광의 배출 장애를 나타내는 증상을 통칭한 하부 요로증상의 호소'로 전립선 비대증을 정의하고 있다.However, recently, the pathological physiology of the disease is too complicated to be explained by the above definitions or concepts, and urinary urination, night urination, and strong and sudden urinary urges to urinate more than eight times a day in men over 50 years old ) Urinary tract and urinary bladder storage symptoms such as urinary urgency and delayed urine (a phenomenon of urinating when urine is seen when urine), urinary discontinuation (phenomena of the flow of urine), urinating force The prostate hyperplasia is defined as the 'appeal of the lower urinary tract symptoms' collectively referred to as a symptom indicating a bladder discharge disorder.
이 질환은 약물로 치료할 수 있는데, 그 중 안드로겐 억제제를 복용하여 치료할 수 있다. 안드로겐 억제제 중 하나인 테스토스테론 5알파-리덕타아제 저해제가 전립선 비대증 치료제로 사용되는데, 시중에서는 피나스테리드(finasteride)와 두타스테리드(dutasteride)가 판매되고 있다. 이들 약제는 안드로겐에 민감한 전립선에서 안드로겐 작용을 억제하여 전립선 크기를 줄이는 작용을 한다. 최근 연구에서는 장기간 복용 시 급성 요폐와 수술 빈도를 감소시켜 전립선 비대증의 진행을 억제하는 데 유용하다는 결과가 보고되었고, 전립선암의 예방 효과에 대한 연구가 활발히 진행 중에 있다. The disease can be treated with medications, including androgen inhibitors. Testosterone 5alpha-reductase inhibitor, one of the androgen inhibitors, is used to treat prostatic hypertrophy, and commercially available finasteride and dutasteride are sold. These drugs act to reduce the size of the prostate by inhibiting androgen action in androgen-sensitive prostates. Recent studies have reported that long-term use of acute urinary tract and surgery reduces the frequency of prostate hyperplasia, and studies on the prophylactic effects of prostate cancer are being actively conducted.
그러나, 복용 후 효과가 나타날 때까지 시간이 오래 걸리고, 성기능을 감소시키는 부작용이 있어 전립선 특이항원(PSA) 수치가 높은 경우와 전립선크기가 큰 경우에만 복용이 권장된다. 수술 치료와 약물 치료로 비대 된 전립선 조직의 절제 수술에 의해 원인적 치료가 가능 하나 환자가 대부분 노인으로 수술대상이 제한되며 수술 후의 부작용 및 재발 등의 문제가 있어 간편한 약물요법에 대한 기대가 증대되고 있다.However, it takes a long time to take effect after taking it, and there is a side effect that decreases sexual function, so it is recommended to take it only when the prostate specific antigen (PSA) level is high and the prostate size is large. Although causative treatment is possible by resection of prostate tissue enlarged by surgical treatment and drug treatment, most patients are restricted to the elderly, and there are problems such as side effects and recurrence after surgery, which increases the expectation for simple drug therapy. have.
한편, 민들레(Taraxacum offininale)는 들이나 길가에 자라는 다년생 초본으로서, 유용한 약리작용을 하는 성분을 다량으로 함유하고 있으므로 동서양에서 모약재로 두루 이용되었다. 한방에서는 건조시킨 민들레를 포공영이라고 하고, 열을 내리고, 소변을 잘 나오게 하고, 염증을 없애며, 위장을 튼튼하게 하고, 독을 풀고 피를 맑게 하는 등의 작용이 있는 것으로 알려져, 강장, 해열, 이뇨, 건위, 거담, 해독 등에 이용되었다. Meanwhile, dandelion ( Taraxacum offininale ) is a perennial herb that grows in fields or on the roadside, and has been used extensively as a herbal medicine in the East and West because it contains a large amount of useful pharmacological ingredients. In oriental medicine, dried dandelion is called pogongyoung, and it is known to work to lower the heat, to urinate well, to remove inflammation, to strengthen the stomach, to detoxify and to clear blood, and tonic, fever, and diuresis. It has been used for health, expectancy, expectation, and detoxification.
가시오가피(Acanthopanax senticosus)는 인삼과 같은 두릅나무과에 속하는 낙엽성 활엽관목으로, 가시오가피나무는 그 생김새가 산삼을 닮아 러시아 및 미주·유럽지역에서는 시베리아 산삼(Siberian Ginseng)으로 불리기도 한다. 가시오가피나무는 생물활성이 뛰어난 아칸토사이드 및 여러 유용성분을 다량 함유하고 있는 것으로 밝혀져 있다. 가시오가피나무는 예전부터 건강을 증진시키는 약용식물 중 하나로 인식되어 그 성분 및 효능에 대하여 다양한 연구가 되어 왔다. 그러한 연구들을 통하여 가시오가피나무의 유용성분은 동물의 선천적 및 특이적 면역계에 작용하여 숙주의 항미생물 및 항종양작용을 항진시킴이 확인되었다. 특히 가시오가피나무의 과실 및 잎에 존재하는 세코트리테르페노이드글리코시드(secotriterpenoid glycoside)의 일종인 지사노사이드(Chiisanoside)는 항암활성 및 신장 독성 저항활성 등의 효능이 있음이 보고되었다. 또한, 가시오가피나무 과실에 함유되어 있는 가시오가피 배당체는 RNA의 합성을 촉진하여 골수 조혈과도 유효적인 효과가 있으며, 가시오가피의 수용성 다당류는 탐식세포의 수를 증가시켜 백혈구를 증가시키는 효능이 있음이 확인되었다. 이러한 다양한 유용성분들을 함유하고 있는 가시오가피는 예로부터 민간 또는 한방에서 중풍, 신경통, 관절염, 고혈압, 신경쇠약, 당뇨를 다스리는 약의 일종으로 사용되고 있다. Acanthopanax senticosus ) is a deciduous broad-leaved shrub belonging to the family Armenian ginseng, such as ginseng. Prickly gingiva tree looks like wild ginseng and is also called Siberian Ginseng in Russia, America and Europe. Prickly Pear Tree has been found to contain a large amount of acantoside and various useful components with excellent biological activity. Thorn oak tree has been recognized as one of the health-promoting plants for a long time and has been studied variously for its composition and efficacy. Through such studies, it has been found that the useful components of prickly oak bark act on the innate and specific immune systems of animals to enhance the antimicrobial and anti-tumor effects of the host. In particular, chisanoside, a type of secotriterpenoid glycoside present in fruits and leaves of prickly oak tree, has been reported to be effective in anticancer activity and kidney toxicity resistance. In addition, it is confirmed that prickly glycoside glycosides contained in prickly pear fruit have an effective effect on bone marrow hematopoiesis by promoting the synthesis of RNA. . Psoriasis containing these various useful ingredients has been used as a medicine for treating stroke, neuralgia, arthritis, hypertension, nervous breakdown and diabetes in folk medicine or traditional medicine.
홍삼은 수삼을 쪄서 말린 붉은 색의 인삼을 말하는 것으로, 대한민국 현행법상 "인삼을 증숙(烝熟) 또는 팽숙(膨熟)하거나 기타의 방법으로 인삼의 녹말을 호화한 것"으로 정의하고 있으며, 신체의 체질을 건강 체질로 항상 유지시켜주는 항상성(恒常性)의 효능에 탁월한 것으로 알려져 있는 등 다양한 질병에 대한 효능이 임상 실험이나 연구를 통해 보고되고 있다. 홍삼에는 수삼이나 백삼과 같이 배당체(glycosides), 인삼향성분(panacen), 폴리아세틸렌계 화합물, 함질소성분, 플라보노이드(flavonoid), 비타민 B군, 미량원소, 효소, 항산화 물질, 유기산, 아미노산 등이 함유되어 있다. 또한, 홍삼은 단순히 인삼을 장기간 보관하기 위하여 제조하는 것은 아니며, 제조공정 중에 우리 몸에 유익한 여러 가지 새로운 생리활성성분들이 생성된다. 즉, 홍삼제조과정에서는 진세노사이드의 열분해에 의한 부분적인 분자구조의 변화로 화학적인 성분이 변화되어 유익한 특수 성분이 생기게 되는데, 수삼이나 백삼 등 다른 인삼에서는 들어있지 않은 홍삼만의 특수성분인 말톨(Maltol)과 진세노사이드(Ginsenosides Rh1, Rh2, Rs1, Rs2, Rg3, Rg5 등)를 비롯한 8종의 특수성분이 들어 있으며, 이 중 말톨(Maltol)은 노화억제기능을 갖고, 진세노사이드(Ginsenosides Rh1, Rh2, Rs1, Rs2, Rg3, Rg5 등)는 항암, 항당뇨, 항궤양, 항염증, 노화방지, 혈관 확장기능, 항 스트레스 등의 활성 기능이 우수한 것으로 알려져 있다.Red ginseng refers to red ginseng that is dried and dried by ginseng, and is defined in Korean law as "ginseng starch ginseng, steamed ginseng, or other ginseng starch." Efficacy of various diseases has been reported through clinical trials and studies, such as being known for being excellent in the efficacy of homeostasis (恒常 性) that always maintains the constitution of health. Like ginseng and white ginseng, red ginseng contains glycosides, panacen, polyacetylene compounds, nitrogen-containing compounds, flavonoids, vitamin B group, trace elements, enzymes, antioxidants, organic acids and amino acids. It is contained. In addition, red ginseng is not simply manufactured for long-term storage of ginseng, and a variety of new bioactive ingredients are produced during the manufacturing process that are beneficial to our body. That is, in the manufacturing process of red ginseng, the chemical composition is changed due to the partial molecular structure change due to the thermal decomposition of ginsenoside, resulting in a beneficial special ingredient. Maltol, a special ingredient of red ginseng which is not contained in other ginseng such as fresh ginseng or white ginseng (Maltol) and ginsenosides (Ginsenosides Rh1, Rh2, Rs1, Rs2, Rg3, Rg5, etc.) contains eight kinds of special ingredients, among which Maltol (Maltol) has an anti-aging function, Ginsenosides (Ginsenosides) Rh1, Rh2, Rs1, Rs2, Rg3, Rg5, etc.) are known to have excellent activity such as anti-cancer, anti-diabetic, anti-ulcer, anti-inflammatory, anti-aging, vasodilation, and anti stress.
금앵자는(Rosa laevigata)의 줄기는 덩굴성으로 가시가 있으며 길게 뻗는다. 잎은 3출복엽으로 작은잎에는 자루가 있고, 타원형이며 길이 2∼4 cm, 나비 1∼2 cm이고 끝은 뾰족하다. 한방에서는 과실을 강장, 강정, 수렴(收斂), 항균 등의 효능이 있어 만성설사, 다뇨, 유정(遺精), 유뇨(遺尿), 식은땀, 만성장염, 대하(帶下), 자궁출혈 등의 치료에 처방한다. The stem of Rosa laevigata is vine-like, spiny and long. The leaves are 3 bilobal, small leaves have sack, oval, 2 ~ 4 cm long, 1 ~ 2 cm butterfly and pointed. In oriental medicine, the fruit is tonic, gangjeong, convergence, antibacterial, etc. It has chronic diarrhea, polyuria, oil well, 유 ureo, cold sweat, chronic enteritis, lobster, uterine bleeding, etc. Prescribe for treatment.
애엽(Artemisia)은 국화과에 속하는 다년생 초본식물로서, 독특한 향기와 맛을 갖고 있다. 어린잎은 식용으로서 쑥떡 등에 이용되고 있으며, 애엽 속의 약리성분으로는 이소쿠마린(isocoumarin), 쿠마린(coumarin), 다이테르펜락톤(diterpenlactone), 플라보노이드(flavonoid), 펠란드렌(phellandrene), 큐프롤(cuprol), 카디넨(cardinene) 등이 밝혀져 있다. 애엽은 기혈(氣血)과 경맥(經脈)을 따뜻하게 하므로 자궁과 하복부가 허약하고 차서 생기는 자궁 출혈, 임신 중 출혈, 토혈, 코피, 각혈에 지혈 반응을 나타낸다. 또한 하초(下焦)가 허약하고 차며 복부에 냉감과 동통이 있는 증상 및 생리불순, 생리통, 대하(帶下) 등에 사용하며 습진, 피부 가려움증에도 효과가 있다. 약리작용으로 지혈작용, 억균작용, 기관지 평활근 이완작용, 진해거담작용, 수면작용, 자궁흥분유도작용, 과민성 쇼크 보호작용, 항암작용, 항균작용 등이 있다. Artemisia is a perennial herbaceous plant belonging to the Asteraceae family and has a unique aroma and taste. The young leaves are used for wormwood rice cake as food, and the pharmacological components of the leaves are isocoumarin, coumarin, dieterlaclactone, flavonoid, phellandrene, cuprol ( cuprol) and cardinene. The lower lobe warms the blood vessels and meridians (經脈), so the uterine and lower abdomen are weak and cold due to uterine bleeding, bleeding during pregnancy, hemostasis, nosebleeds, and hemostasis. In addition, Hacho is weak and cold, cold and painful symptoms in the abdomen, menstrual disorders, menstrual pain, daeha (帶下), etc. It is effective in eczema and itching of the skin. Pharmacological actions include hemostatic action, fungal action, bronchial smooth muscle relaxation action, antitussive expectoration action, sleep action, uterus excitement action, hypersensitivity shock protection, anticancer action, antibacterial action.
은행잎(Ginkgo biloba L.)은 천식과 기관지염의 치료약으로 약 5,000년 전부터 사용하였다는 사실이 중국 약전에 기재되어 있으며 지금도 여전히 그 약효가 평가되고 있다. 근래에는 아시아와 유럽 등지에서 노인성 말초 순환장애, 뇌혈관 장애 및 천식 치료제로 널리 사용되고 있다. 은행잎 추출물은 1972년 유럽에서 특허화되어 심혈관계의 치료제로 널리 사용되고 있는데, 이와 같은 은행잎의 약리작용은 주로 은행잎 성분 중 플라보노이드계 화합물과 테르펜계 화합물에 의하는 것으로 알려져 있다. 테르펜계 화합물에는 빌로발라이드, 깅콜라이드 A, B, C, D, M, J 등이 있는데, 깅콜라이드는 ADP(Adenosine diphosphate), 아라키돈 산, 콜라겐, 트롬빈 등과 같은 길항제에 의해 유도되는 혈소판 응집은 억제하지 못하나 혈소판 활Ginkgo Leaves biloba L. ) has been used as a medicine for asthma and bronchitis for about 5,000 years, and it is still being evaluated. Recently, it is widely used in Asia and Europe as an agent for treating peripheral circulatory disorders, cerebrovascular disorders and asthma. The ginkgo biloba extract was patented in Europe in 1972 and is widely used as a therapeutic agent for the cardiovascular system. The pharmacological action of the ginkgo biloba leaves is mainly known to be based on flavonoid compounds and terpene compounds. Terpene compounds include bilovalide, gingcholides A, B, C, D, M, and J. Gingcholides are platelets induced by antagonists such as Adenosine diphosphate (ADP), arachidonic acid, collagen, and thrombin. It does not inhibit aggregation but platelet bow
성인자에 의해 유도되는 혈소판 응집만을 선택적으로 억제하는 강력한 길항제로 보고되면서부터 그 관심이 매우 높아지고 있다. 깅콜라이드는 이러한 혈소판 활성인자와의 경쟁적 반응으로 천식, 기관지염, 노인성 치매, 알레르기, 심장질환, 쇼크증상, 류마티스 질환, 기타 순환기 질환에 유용하게 이용되고 있다.Interest has been very high since it has been reported as a potent antagonist that selectively inhibits only platelet aggregation induced by adults. Gingcolide is a competitive reaction with platelet activators and is useful for asthma, bronchitis, senile dementia, allergies, heart disease, shock symptoms, rheumatic diseases and other circulatory diseases.
이에 본 발명은 민들레 추출물, 가시오가피 추출물, 홍삼 추출물, 금앵자 추출물, 애엽 추출물 또는 은행잎 추출물을 첨가한 조성물이 테스토스테론 5알파-리덕타아제를 저해함을 확인하고, 탈모 또는 전립선 비대증을 예방을 위한 조성물로 개발하여 제공하는데 그 목적이 있다.Therefore, the present invention confirms that the composition to which the dandelion extract, prickly pear extract, red ginseng extract, golden primrose extract, leafy leaf extract or ginkgo biloba extract inhibits testosterone 5alpha-reductase, and prevents hair loss or enlarged prostate. The purpose is to develop and provide.
상기 목적을 달성하기 위하여, 본 발명은 민들레 추출물, 가시오가피 추출물, 홍삼 추출물, 금앵자 추출물, 애엽 추출물 및 은행잎 추출물 중 선택되는 어느 하나 이상을 포함하는 것을 특징으로 하는 탈모 예방용 조성물을 제공한다. 본 발명에서는 162개의 천연물 시료를 대상으로 테스토스테론 5알파-리덕타아제 활성저해 시험을 하여 30% 이상 억제률을 보이는 소재를 선별하였다. 시험결과, 민들레 추출물, 가시오가피 추출물, 홍삼 추출물, 금앵자 추출물, 애엽 추출물 또는 은행잎 추출물이 30% 이상의 억제률을 보이는 것으로 확인되었다. In order to achieve the above object, the present invention provides a composition for preventing hair loss, characterized in that it comprises any one or more selected from dandelion extract, prickly pear extract, red ginseng extract, golden primrose extract, leaf extract and ginkgo leaf extract. In the present invention, a testosterone 5 alpha-reductase inhibitory test was performed on 162 natural products to select materials showing an inhibition rate of 30% or more. As a result of the test, it was confirmed that the dandelion extract, prickly pear extract, red ginseng extract, golden primrose extract, leafy leaf extract or ginkgo leaf extract showed more than 30% inhibition rate.
한편, 본 발명의 탈모 예방용 조성물에 있어서, 상기 조성물은 바람직하게 민들레 추출물, 가시오가피 추출물 및 홍삼 추출물을 포함하는 것이 좋다. 본 발명에서 확인된 30% 이상의 억제률을 보이는 시료 6가지 중 민들레 추출물, 가시오가피 추출물, 홍삼 추출물을 함께 조성할 경우 제일 높은 시너지 효과가 나타나기 때문이다. On the other hand, in the composition for preventing hair loss of the present invention, the composition preferably comprises dandelion extract, prickly pear extract and red ginseng extract. This is because the highest synergistic effect is achieved when the dandelion extract, prickly pear extract, and red ginseng extract are combined together among the six samples showing the inhibition rate of 30% or more.
한편, 본 발명의 탈모 예방용 조성물에 있어서, 상기 조성물은 일 예로 술일 수 있다. 본 발명에서 선별된 6가지 소재를 추출 분말로 수득한 후, 술에 첨가하여 칵테일 형태의 술로 제조할 수 있는 것이다. On the other hand, in the composition for preventing hair loss of the present invention, the composition may be alcohol as an example. The six materials selected in the present invention are obtained as extract powders, and then added to alcohol to produce alcohol in the form of cocktails.
한편, 본 발명의 탈모 예방용 조성물에 있어서, 상기 추출물은 바람직하게 추출용매로 에탄올 수용액을 사용한 것이 좋다. 에탄올 수용액을 사용하는 경우 유용 추출이 용이하기 때문이다. On the other hand, in the composition for preventing hair loss of the present invention, the extract is preferably used an aqueous solution of ethanol as the extraction solvent. This is because useful extraction is easy when an aqueous ethanol solution is used.
한편, 본 발명의 탈모 예방용 조성물에 있어서, 상기 탈모 예방은 탈모와 관련되는 테스토스테론 5알파-리덕타아제(5α-reductase) 효소를 저해하여 탈모를 억제하는 것이다. On the other hand, in the composition for preventing hair loss of the present invention, the prevention of hair loss is to inhibit hair loss by inhibiting the testosterone 5 alpha-reductase enzyme associated with hair loss.
한편, 본 발명은 민들레 추출물, 가시오가피 추출물, 홍삼 추출물, 금앵자 추출물, 애엽 추출물 및 은행잎 추출물 중 선택되는 어느 하나 이상을 포함하는 것을 특징으로 하는 전립선 비대증 예방용 조성물을 제공한다. On the other hand, the present invention provides a composition for preventing prostatic hyperplasia, characterized in that it comprises any one or more selected from dandelion extract, prickly pear extract, red ginseng extract, golden primrose extract, leaf leaf extract and ginkgo leaf extract.
한편, 본 발명의 전립선 비대증 예방용 조성물에 있어서, 상기 조성물은 바람직하게 민들레 추출물, 가시오가피 추출물 및 홍삼 추출물을 포함하는 것이 좋다. On the other hand, in the composition for preventing the enlargement of the prostate gland of the present invention, the composition preferably comprises dandelion extract, prickly pear extract and red ginseng extract.
한편, 본 발명의 전립선 비대증 예방용 조성물에 있어서, 상기 조성물은 일 예로 술일 수 있다.On the other hand, in the composition for preventing the enlargement of the prostate gland of the present invention, the composition may be an example.
한편, 본 발명의 전립선 비대증 예방용 조성물에 있어서, 상기 추출물은 바람직하게 추출용매로 에탄올 수용액을 사용한 것이 좋다.On the other hand, in the composition for preventing the enlargement of the prostate gland of the present invention, the extract is preferably used an aqueous solution of ethanol as the extraction solvent.
한편, 본 발명의 전립선 비대증 예방용 조성물에 있어서, 상기 전립선 비대증 예방은 전립성 비대증과 관련되는 테스토스테론 5알파-리덕타아제(5α-reductase) 효소를 저해하여 탈모를 억제하는 것이다.On the other hand, in the composition for preventing prostatic hyperplasia of the present invention, the prevention of prostatic hyperplasia is to inhibit hair loss by inhibiting the testosterone 5 alpha-reductase enzyme associated with prostatic hyperplasia.
본 발명에 의하면, 민들레 추출물, 가시오가피 추출물, 홍삼 추출물, 금앵자 추출물, 애엽 추출물 또는 은행잎 추출물에 탈모 또는 전립선 비대증과 관련 있는 테스토스테론 5알파-리덕타아제(5α-reductase)의 저해능이 있음이 확인되었다. According to the present invention, it was confirmed that dandelion extract, prickly pear extract, red ginseng extract, golden primrose extract, leafy leaf extract or ginkgo biloba extract have an inhibitory effect of testosterone 5alpha-reductase related to hair loss or enlarged prostate. .
이와 같은 결과를 바탕으로 본 발명에서는 탈모 예방용 조성물 또는 전립선 비대증 예방용 조성물을 제조할 수 있다.
Based on the results, the present invention can prepare a composition for preventing hair loss or a composition for preventing prostatic hyperplasia.
이하, 본 발명의 내용을 하기 실시예를 들어 더욱 상세히 설명하고자 한다. 다만, 본 발명의 권리범위가 하기 실시예에만 한정되는 것은 아니고, 그와 등가의 기술적 사상의 변형까지를 포함한다.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the scope of the present invention is not limited to the following embodiments, and includes modifications of equivalent technical ideas.
[[ 실시예Example 1: 162개 시료 추출물 제조방법] 1: 162 sample extract preparation method]
162개 천연물을 곱게 분쇄하여 제조한 시료 10 g에 에탄올, 70% 에탄올 또는 물을 200 ㎖ 넣고 초음파세정기를 이용하여 1시간 동안 추출하였다. 제조된 추출물을 감압회전농축기(Eyela N-1000, Tokyo, Japan)로 감압농축하여 162개의 추출물을 얻었다. 상기 추출물 162개에 대해 66.67 ㎍/㎖ 농도에서 테스토스테론 5알파-리덕타아제 활성억제를 시험하고자 하였다. 200 g of ethanol, 70% ethanol or water was added to 10 g of a sample prepared by grinding finely 162 natural products, and extracted for 1 hour using an ultrasonic cleaner. The extracts were concentrated under reduced pressure with a vacuum rotary concentrator (Eyela N-1000, Tokyo, Japan) to obtain 162 extracts. Testosterone 5 alpha-reductase activity inhibition was intended to test the 162 extracts at a concentration of 66.67 μg / ml.
한편, 본 실험에 필요한 테스토스테론 5알파-리덕타아제 효소는 다음과 같이 제조하였다. 24시간 절식한 래트(rat)의 간장을 빙냉한 크랩스 링거 완충액(krebs-Ringer phosphate buffer, pH 7.2)으로 관류하여 혈액을 제거하였다. 여기에 1.4배 양의 빙냉한 0.01 M 트리스 염화수소 완충액(Tris-HCl buffer, pH 7.2)을 가하여 균질화하고, 3000 rpm, 4℃에서 10분간 원심분리하였다. 원심분리하여 분리된 상층을 7,000 rpm, 4℃에서 10분간 다시 원심분리하고, 여기서 분리된 상층액을 10,000 rpm, 4℃에서 10분간 한번 더 원심분리하여 얻어진 상층액을 효소액으로 사용하였다. 효소액은 -70℃에서 동결보존하여 실험에서 사용하였다. On the other hand, testosterone 5 alpha-reductase enzyme required for this experiment was prepared as follows. The livers of rats fasted for 24 hours were perfused with ice-cold Crabs-Ringer phosphate buffer (pH 7.2) to remove blood. A 1.4-fold ice-cold 0.01 M Tris hydrogen chloride buffer (Tris-HCl buffer, pH 7.2) was added to homogenize and centrifuged at 3000 rpm and 4 degreeC for 10 minutes. The supernatant separated by centrifugation was centrifuged again at 7,000 rpm at 4 ° C. for 10 minutes, and the supernatant obtained by centrifuging the separated supernatant once more at 10,000 rpm at 4 ° C. for 10 minutes was used as the enzyme solution. The enzyme solution was cryopreserved at -70 ° C and used in the experiment.
실험을 위해, 테스토스테론(Testosterone, 500 ㎍/㎖) 50 ㎕, 상기에서 수득한 시료를 각각 녹인 시험액 50 ㎕, 상기에서 제조한 테스토스테론 5알파-리덕타아제 효소액 160 ㎕를 혼합하고, NADPH(0.77 ㎎/㎖) 80 ㎕, 2 mM 디티오토레이톨(dithiothreitol) 400 ㎕를 가하여 반응을 개시한 다음 37℃에서 30분간 인큐베이션하였다. 디클로로메탄(Dichloromethane)에 내부표준물질(p-hydroxybenzoic acid n-hexyl ester, 0.01 mg/㎖)을 녹인 다음 820 ㎕를 넣어 상기 반응을 정지시켰다. 그 후, 볼텍싱(vortexing)하여 상하를 잘 섞이게 한 다음 3,000 rpm에서 10분간 원심분리하고, 상층을 제거한 후, 디클로로메탄(Dichloromethane)층을 질소로 날렸다. 여기에 메탄올(Methanol) 500 ㎕를 가하고, 고속액체크로마토그래피(HPLC)로 남아있는 테스토스테론(Testosterone)량을 측정하여 테스토스테론 5알파-리덕타아제 활성 억제률을 하기 수학식 1과 같이 계산하여 '%'로 나타내었다. For the experiment, 50 μl of Testosterone (500 μg / ml), 50 μl of the test solution obtained by dissolving the sample obtained above, 160 μl of the testosterone 5 alpha-reductase enzyme solution prepared above were mixed, and NADPH (0.77 mg). / Ml) 80 μl, 400 μl 2 mM dithiothreitol were added to initiate the reaction, and then incubated at 37 ° C. for 30 minutes. The reaction was stopped by dissolving an internal standard (p-hydroxybenzoic acid n-hexyl ester, 0.01 mg / mL) in dichloromethane and adding 820 μl. Then, vortexing (vortexing) to mix the upper and lower well, centrifuged for 10 minutes at 3,000 rpm, and after removing the upper layer, the dichloromethane layer was blown with nitrogen. Add 500 μl of methanol and measure the amount of testosterone remaining by high performance liquid chromatography (HPLC) to calculate the testosterone 5 alpha-reductase activity inhibition rate as shown in Equation 1 below. '
한편, 테스토스테론 5알파-리덕타아제 활성억제 실험의 양성대조군으로는 시중에서 테스토스테론 5알파-리덕타아제 저해제로 사용중인 피나스테라이드(Finasteride)와 여성 호르몬 계열인 에치닐에스트라디올(Ethinylestradiol)을 사용하였다.On the other hand, as a positive control group of testosterone 5 alpha-reductase activity inhibitory experiment, Finasteride (Finasteride), which is currently used as a testosterone 5 alpha-reductase inhibitor, and the female hormone family ethynylestradiol were used.
한편, 고속액체크로마토그래피(HPLC)의 측정조건은 다음과 같았다. 컬럼(Column)은 Thermo Hypersil Gold C18(150×4.6 mm) 사용하였고, 이동상으로는 메탄올과 물을 65:35의 비율로 혼합하여 사용하였다. 유속은 1.0 ㎖/min, 컬럼온도는 40℃, 주입량은 20 ㎕, 검출파장은 254 nm에서 측정하였다. 측정은 내부표준물질법을 이용하였고, 피크-면적 비(테스토스테론/내부표준물질)로 테스토스테론 5알파-리덕타아제 억제률을 % 값으로 나타내었다 (수학식 1).On the other hand, the measurement conditions of high performance liquid chromatography (HPLC) were as follows. As a column, Thermo Hypersil Gold C18 (150 × 4.6 mm) was used, and as a mobile phase, methanol and water were mixed at a ratio of 65:35. The flow rate was 1.0 ml / min, the column temperature was 40 ° C., the injection amount was 20 μl, and the detection wavelength was measured at 254 nm. The measurement was performed using the internal standard method, and the testosterone 5 alpha-reductase inhibition rate was expressed as a% value by the peak-area ratio (testosterone / internal standard) (Equation 1).
[수학식 1] [Equation 1]
억제률(%)=100×{(테스트 샘플의 면적 - 30분동안 반응이 진행된 샘플의 면적/(0분동안에서 반응이 정지된 샘플의 면적 - 30분동안 반응이 진행된 샘플의 면적)}
% Inhibition = 100 x {area of test sample-area of the sample which has been reacted for 30 minutes / (area of the sample which has been stopped for 0 minutes-area of the sample which has been reacted for 30 minutes)}
실험 결과, 30% 이상의 억제률을 보이는 소재로 민들레, 가시오가피, 홍삼, 금앵자, 애엽, 은행잎을 선별하였다(표 1, 2 및 3 참조). 한편, 양성대조군인 피나스테라이드(Finasteride)는 26%로, 또 다른 양성대조군인 에치닐에스트라디올(Ethinylestradiol)은 46%로 나타났다.
As a result, dandelion, prickly pear, red ginseng, golden primrose, leaf lobe, ginkgo biloba leaf were selected as the material showing more than 30% inhibition rate (see Tables 1, 2 and 3). On the other hand, 26% of the positive control finasteride (Finasteride), 46% of the other positive control group Ethinylestradiol (Ethinylestradiol).
(%) Inhibition rate
(%)
(%) Inhibition rate
(%)
(%) Inhibition rate
(%)
(%) Inhibition rate
(%)
버섯 Roe deer
mushroom
(%) Inhibition rate
(%)
(%) Inhibition rate
(%)
[[ 실시예Example 2: 활성시료의 추출물 제조 및 2: preparation of active sample extract and 건강주Health stock 제조] Produce]
민들레, 가시오가피, 홍삼, 금앵자, 애엽, 은행잎 각각의 100 g에 주정 2 L를 넣고 반응조(MS-CM709) 100℃에서 3시간 동안 환류 추출하였다. 본 발명에서 타겟으로 하는 조성물의 형태가 술이므로, 추출용매로 주정을 사용하였다. 상기의 방법에 의해 제조된 민들레 추출물, 가시오가피 추출물, 홍삼 추출물, 금앵자 추출물, 애엽 추출물, 은행잎 추출물 각각을 감압회전농축기(Eyela N-1000, Tokyo, Japan)를 이용하여 감압농축하였다. 상기 감압농축된 추출물을 동결건조하여 민들레 추출물 23 g, 가시오가피 추출물 24 g, 홍삼 추출물 7.5 g, 금앵자 추출물 18 g, 애엽 추출물 21 g, 은행잎 추출물 13 g의 시료를 얻었다. 2 g of alcohol was added to 100 g of each of dandelion, prickly pear, red ginseng, golden cherry, leafy leaf, and ginkgo biloba and refluxed for 3 hours at 100 ° C in a reaction tank (MS-CM709). Since the form of the composition targeted in the present invention is liquor, alcohol was used as the extraction solvent. Dandelion extract, prickly pear extract, red ginseng extract, golden primrose extract, leafy leaf extract, ginkgo leaf extract prepared by the above method were concentrated under reduced pressure using a reduced pressure rotary concentrator (Eyela N-1000, Tokyo, Japan). The extract was concentrated under reduced pressure and lyophilized to obtain a sample of dandelion extract 23 g, prickly pear extract 24 g, red ginseng extract 7.5 g, golden primrose extract 18 g, leaf extract 21 g, ginkgo leaf extract 13 g.
한편, 상기 얻어진 추출물 10중량%를 소주에 첨가하여 칵테일 형태의 건강주를 제조하였다.
Meanwhile, 10% by weight of the obtained extract was added to the soju to prepare a cocktail of healthy liquor.
[[ 실시예Example 3: 선별된 6가지 활성시료의 테스토스테론 3: Testosterone from six selected active samples 5알파5 Alpha -- 리덕타아제Reductase 활성억제 시너지 효능평가] Activity Inhibition Synergy Effect Assessment]
선별된 6가지 활성시료의 시너지 효능을 평가하고자 하였다. 먼저, 민들레 추출물, 가시오가피 추출물, 홍삼 추출물, 금앵자 추출물, 애엽 추출물 또는 은행잎 추출물의 50% 억제률(IC50)을 구하고, 30% 효능이 있는 EC30% (30% of the effect concentration)에 해당되는 농도를 여러 가지 배합비율로 (3종, 4종, 5종, 6종)혼합하여 테스토스테론 5알파-리덕타아제 활성억제시험에 이용하였다. 측정 방법은 실시예 1과 동일한 방법으로 하였다. To evaluate the synergistic efficacy of six selected active samples. First, obtain 50% inhibition rate (IC 50 ) of dandelion extract, prickly pear extract, red ginseng extract, golden primrose extract, leafy leaf extract or ginkgo biloba extract. The concentrations were mixed in various proportions (3, 4, 5, 6) and used for testosterone 5 alpha-reductase activity inhibition test. The measuring method was the same as that of Example 1.
측정 결과, IC50은 하기 표 4와 같았다. As a result, IC 50 was as Table 4 below.
(Ethinylestradiol) Ethinyl estradiol
(Ethinylestradiol)
163.94
163.94
(Finasteride) Finasteride
(Finasteride)
36.09
36.09
민들레 추출물
Dandelion extract
224.80
224.80
금앵자 추출물
Golden Primrose Extract
548,52
548,52
애엽 추출물
Leaf extract
255.36
255.36
가시오가피 추출물
Prickly Pear Extract
377.95
377.95
은행잎 추출물
Ginkgo Leaf Extract
193.66
193.66
홍삼 추출물
Red Ginseng Extract
444.25
444.25
한편, EC30%은 하기 표5와 같았다. On the other hand, EC30% was as shown in Table 5.
(㎍/㎖)dandelion
(占 퐂 / ml)
(㎍/㎖)Golden cherry
(占 퐂 / ml)
(㎍/㎖)Love
(占 퐂 / ml)
(㎍/㎖)Go away
(占 퐂 / ml)
(㎍/㎖)Ginkgo leaf
(占 퐂 / ml)
(㎍/㎖)Red ginseng
(占 퐂 / ml)
(%)Inhibition rate
(%)
상기 표 5에서 확인되는 바와 같이 민들레 추출물은 40.84 ㎍/㎖, 금앵자 추출물 50.15 ㎍/㎖, 애엽 추출물 ㎍/㎖, 가시오가피 추출물 14.97 ㎍/㎖, 은행잎 추출물 54.68 ㎍/㎖, 홍삼 추출물 25.36 ㎍/㎖에서 테스토스테론 5알파-리덕타아제를 30% 억제하는 것으로 확인되었다.
As confirmed in Table 5, the dandelion extract 40.84 ㎍ / ㎖, Golden Primrose extract 50.15 ㎍ / ㎖, leafy leaf extract ㎍ / ㎖, thorny goose extract 14.97 ㎍ / ㎖, ginkgo biloba extract 54.68 ㎍ / ㎖, red ginseng extract 25.36 ㎍ / ㎖ Has been shown to inhibit testosterone 5alpha-reductase by 30%.
한편, 상기 표 5의 EC30% 농도를 이용하여 배합비율을 정하고 시료 3종, 4종, 5종, 6종을 각각 혼합하여 총 볼륨 50 ㎕를 반응시켜 시너지 효능증가률(%)을 계산하였다(표 6). 시너지 효능 증가률은 하기 수학식 2를 이용하여 계산하였다.Meanwhile, the compounding ratio was determined using the EC30% concentration of Table 5, and three, four, five, and six samples were mixed, respectively, and 50 µl of the total volume was reacted to calculate the synergistic growth rate (%). 6). Synergy efficacy increase rate was calculated using the following equation (2).
[수학식 2]&Quot; (2) "
시너지 효능 증가률(%)={(억제률%-30%)/30%}×100 Synergistic potency increase rate (%) = {(inhibition rate% -30%) / 30%} × 100
추출물
(㎍/㎖)dandelion
extract
(占 퐂 / ml)
추출물
(㎍/㎖)Golden cherry
extract
(占 퐂 / ml)
추출물
(㎍/㎖)Love
extract
(占 퐂 / ml)
추출물
(㎍/㎖)Go away
extract
(占 퐂 / ml)
추출물
(㎍/㎖)Ginkgo leaf
extract
(占 퐂 / ml)
추출물
(㎍/㎖)Red ginseng
extract
(占 퐂 / ml)
(%)Inhibition rate
(%)
실험 결과, 상기 표 6에서 확인되는 바와 같이, 6종 모두 혼합한 조성에서는 시너지 효과가 나타나지 않았고, 3종을 혼합한 민들레 추출물, 가시오가피 추출물, 홍삼 추출물(NO. 9) 조성에서 39.07%로 가장 높은 시너지 효능증가률을 나타내었다.
As a result of the experiment, as shown in Table 6, there was no synergy effect in the composition of all six species, the highest at 39.07% in the composition of dandelion extract, prickly pear extract, red ginseng extract (NO. 9) mixed three species Synergy efficacy growth rate is shown.
한편, 가장 높은 시너지 효능증가률을 보인 NO. 9(민들레 추출물, 가시오가피 추출물, 홍삼 추출물)의 배합비율을 하기 표 7과 같이 달리하여 시너지 효능증가률(%)을 측정하였다(표 7). 총 볼륨 50 ㎕를 넣어 반응시켰으며, 시너지 효능증가률(%)은 상기 수학식 2로 계산하였다.On the other hand, NO. Synthesis ratio (%) of 9 (dandelion extract, prickly pear extract, red ginseng extract) was measured as shown in Table 7 below (Table 7). 50 μl of the total volume was added and reacted, and the synergy increase rate (%) was calculated by the above Equation 2.
추출물
(㎍/㎖)dandelion
extract
(占 퐂 / ml)
추출물
(㎍/㎖)Go away
extract
(占 퐂 / ml)
추출물
(㎍/㎖)Red ginseng
extract
(占 퐂 / ml)
(%)Inhibition rate
(%)
증가률(%)Synergy
% Growth
실험결과, 상기 표 7에서 확인되는 바와 같이, 민들레 추출물, 가시오가피 추출물, 홍삼 추출물을 혼합한 조성에서는 1번 조건이 47.05%로 가장 높은 시너지 효능증가률을 나타내었다.Experimental results, as confirmed in Table 7, the composition of the dandelion extract, prickly pear extract, red ginseng extract showed the highest synergy efficacy growth rate of 47.05%.
Claims (10)
Hair loss prevention composition, characterized in that it comprises any one or more selected from dandelion extract, prickly pear extract, red ginseng extract, golden primrose extract, leaf extract and ginkgo leaf extract.
상기 조성물은,
민들레 추출물, 가시오가피 추출물 및 홍삼 추출물을 포함하는 것을 특징으로 하는 탈모 예방용 조성물.
The method of claim 1,
The composition may comprise,
Hair loss prevention composition comprising dandelion extract, prickly pear extract and red ginseng extract.
상기 조성물은,
술인 것을 특징으로 하는 탈모 예방용 조성물.
The method of claim 1,
The composition may comprise,
Hair loss prevention composition characterized in that the liquor.
상기 추출물은,
추출용매로 에탄올 수용액을 사용한 것을 특징으로 하는 탈모 예방용 조성물.
The method of claim 1,
The above-
A composition for preventing hair loss, characterized in that an aqueous solution of ethanol is used as the extraction solvent.
상기 탈모 예방은,
탈모와 관련되는 테스토스테론 5알파-리덕타아제(5α-reductase) 효소를 저해하여 탈모를 억제하는 것을 특징으로 하는 탈모 예방용 조성물.
The method of claim 1,
The hair loss prevention,
A composition for preventing hair loss, characterized by inhibiting hair loss by inhibiting testosterone 5 alpha-reductase enzyme related to hair loss.
A composition for preventing prostatic hyperplasia, characterized in that it comprises any one or more selected from dandelion extract, thorny opi extract, red ginseng extract, golden primrose extract, leaf extract and ginkgo leaf extract.
상기 조성물은,
민들레 추출물, 가시오가피 추출물 및 홍삼 추출물을 포함하는 것을 특징으로 하는 전립선 비대증 예방용 조성물.
The method according to claim 6,
The composition may comprise,
A composition for preventing prostatic hyperplasia, comprising dandelion extract, prickly pear extract and red ginseng extract.
상기 조성물은,
술인 것을 특징으로 하는 전립선 비대증 예방용 조성물.
The method according to claim 6,
The composition may comprise,
Prostate hypertrophy composition, characterized in that the liquor.
상기 추출물은,
추출용매로 에탄올 수용액을 사용한 것을 특징으로 하는 전립선 비대증 예방용 조성물.
The method according to claim 6,
The above-
A composition for preventing prostate hyperplasia, characterized in that an aqueous solution of ethanol is used as the extraction solvent.
상기 전립선 비대증 예방은,
전립선 비대와 관련되는 테스토스테론 5알파-리덕타아제(5α-reductase) 효소를 저해하여 전립선 비대증을 억제하는 것을 특징으로 하는 전립선 비대증 예방용 조성물.
The method according to claim 6,
The prostate enlargement prevention,
A composition for preventing prostatic hyperplasia, characterized by inhibiting testosterone 5alpha-reductase enzyme associated with prostatic hypertrophy to inhibit prostatic hyperplasia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120002130A KR101381831B1 (en) | 2012-01-06 | 2012-01-06 | Composition and Health Liquor Containing the Extract of Dandelion, Siberian-ginseng, Red ginseng, Cherokee rose, Mugwort and Ginkgo leaf |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120002130A KR101381831B1 (en) | 2012-01-06 | 2012-01-06 | Composition and Health Liquor Containing the Extract of Dandelion, Siberian-ginseng, Red ginseng, Cherokee rose, Mugwort and Ginkgo leaf |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130081131A true KR20130081131A (en) | 2013-07-16 |
KR101381831B1 KR101381831B1 (en) | 2014-04-14 |
Family
ID=48992963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120002130A KR101381831B1 (en) | 2012-01-06 | 2012-01-06 | Composition and Health Liquor Containing the Extract of Dandelion, Siberian-ginseng, Red ginseng, Cherokee rose, Mugwort and Ginkgo leaf |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101381831B1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103725574A (en) * | 2014-01-17 | 2014-04-16 | 黄增琼 | Method for preparing rosa laevigata and wolfberry fruit wine as well as health-care functions and application of rosa laevigata and wolfberry fruit wine |
CN104208184A (en) * | 2014-09-11 | 2014-12-17 | 陈远征 | Pharmaceutical composition for treating benign prostatic hyperplasia |
CN106539923A (en) * | 2016-12-09 | 2017-03-29 | 广东合百草制药有限公司 | A kind of concocting method of fruit of Cherokee rose meat |
KR20180084339A (en) * | 2017-01-16 | 2018-07-25 | 대구한의대학교산학협력단 | Pharmaceutical composition comprising Korean medicinal herbs for preventing hair loss, melanizing of hair, enhancing hair growth, treating benign prostate hyperplasia and manufacturing method thereof |
WO2019112348A1 (en) * | 2017-12-06 | 2019-06-13 | 주식회사 바이로메드 | Herbal composition for preventing or treating benign prostatic hyperplasia disease |
WO2019124757A1 (en) * | 2017-12-19 | 2019-06-27 | 게놈앤메디신(주) | Composition for prevention, treatment or amelioration of prostate disease comprising extracts of acanthopanacis cortex, phragmitis rhizoma, and pinus densiflora as active ingredient |
KR102022263B1 (en) * | 2018-05-18 | 2019-09-18 | 윤제훈 | A composition comprising the fermented extract of Cinnamomum verum J. Presl, Ulmus davidiana var. japonica da and Acanthopanax sessiliflorum Seeman for preventing and treating benign prostatic hyperplasia |
KR20210004208A (en) * | 2019-07-03 | 2021-01-13 | 경희대학교 산학협력단 | Pharmaceutical composition for the prevention and treatment of benign prostatic hyperplasia, comprising extract of Rosa laevigata Michx. and Cinnamomum cassia (L.) J.Presl |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4033981B2 (en) * | 1998-09-24 | 2008-01-16 | ツムラ ライフサイエンス株式会社 | Testosterone 5α-reductase inhibitor |
KR20070056207A (en) * | 2005-11-29 | 2007-06-04 | 주식회사 엘지생활건강 | Testosterone 5alpha-reductase inhibitor containing vitis radix extract |
KR100950437B1 (en) * | 2007-11-19 | 2010-04-02 | 게놈앤메디신(주) | Herbal composition for the prevention of depilation and improvement of hair growth and method for preparing the same |
KR100846572B1 (en) * | 2008-02-14 | 2008-07-15 | 동아제약주식회사 | Pharmaceutical composition for the preventing loss of hair and promoting growth of hair comprising the extracts of canavalia gladiata |
-
2012
- 2012-01-06 KR KR1020120002130A patent/KR101381831B1/en active IP Right Grant
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103725574A (en) * | 2014-01-17 | 2014-04-16 | 黄增琼 | Method for preparing rosa laevigata and wolfberry fruit wine as well as health-care functions and application of rosa laevigata and wolfberry fruit wine |
CN104208184A (en) * | 2014-09-11 | 2014-12-17 | 陈远征 | Pharmaceutical composition for treating benign prostatic hyperplasia |
CN106539923A (en) * | 2016-12-09 | 2017-03-29 | 广东合百草制药有限公司 | A kind of concocting method of fruit of Cherokee rose meat |
KR20180084339A (en) * | 2017-01-16 | 2018-07-25 | 대구한의대학교산학협력단 | Pharmaceutical composition comprising Korean medicinal herbs for preventing hair loss, melanizing of hair, enhancing hair growth, treating benign prostate hyperplasia and manufacturing method thereof |
CN111465403A (en) * | 2017-12-06 | 2020-07-28 | 赫利世弥斯株式会社 | Herbal composition for preventing or treating prostatic hypertrophy |
KR20190067126A (en) | 2017-12-06 | 2019-06-14 | 주식회사 헬릭스미스 | Herbal Compositions for Treating and Preventing Benign Prostatic Hyperplasia |
WO2019112348A1 (en) * | 2017-12-06 | 2019-06-13 | 주식회사 바이로메드 | Herbal composition for preventing or treating benign prostatic hyperplasia disease |
JP2021505628A (en) * | 2017-12-06 | 2021-02-18 | ヘリックスミス カンパニー, リミテッド | Herbal composition for the prevention or treatment of benign prostatic hyperplasia disease |
WO2019124757A1 (en) * | 2017-12-19 | 2019-06-27 | 게놈앤메디신(주) | Composition for prevention, treatment or amelioration of prostate disease comprising extracts of acanthopanacis cortex, phragmitis rhizoma, and pinus densiflora as active ingredient |
CN110177562A (en) * | 2017-12-19 | 2019-08-27 | 基因组&医学 | It is prevented, treated comprising cortex acanthopanacis, reed root and Japanese red pine extract as the prostatic disorders of effective component or improvement composition |
JP2021508735A (en) * | 2017-12-19 | 2021-03-11 | ゲノム アンド メディスン カンパニー リミテッドGenome & Medicine Co.,Ltd. | Composition for prevention, treatment, or improvement of prostate disease containing Gokahi, Vulpix, and Japanese red pine extract as active ingredients |
US11202815B2 (en) | 2017-12-19 | 2021-12-21 | Genome & Medicine Co., Ltd. | Composition for preventing, treating or improving prostate disease containing acanthopanax sessiliflorus, phragmites rhizome, and pinus densiflora extracts as active ingredient |
KR102022263B1 (en) * | 2018-05-18 | 2019-09-18 | 윤제훈 | A composition comprising the fermented extract of Cinnamomum verum J. Presl, Ulmus davidiana var. japonica da and Acanthopanax sessiliflorum Seeman for preventing and treating benign prostatic hyperplasia |
KR20210004208A (en) * | 2019-07-03 | 2021-01-13 | 경희대학교 산학협력단 | Pharmaceutical composition for the prevention and treatment of benign prostatic hyperplasia, comprising extract of Rosa laevigata Michx. and Cinnamomum cassia (L.) J.Presl |
Also Published As
Publication number | Publication date |
---|---|
KR101381831B1 (en) | 2014-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101381831B1 (en) | Composition and Health Liquor Containing the Extract of Dandelion, Siberian-ginseng, Red ginseng, Cherokee rose, Mugwort and Ginkgo leaf | |
Jamil et al. | Centella asiatica (Linn.) Urban—a review | |
Kumar et al. | 5α-reductase inhibition and hair growth promotion of some Thai plants traditionally used for hair treatment | |
Shrikant Baslingappa et al. | Jamun (Syzygium cumini (L.)): A review of its food and medicinal uses | |
Sood et al. | A review on ethnomedicinal, phytochemical and pharmacological aspects of Myrica esculenta. | |
EP2857032A2 (en) | Tie2 activator, vascular endothelial growth factor (vegf) inhibitor, anti-angiogenic agent, agent for maturing blood vessels, agent for normalizing blood vessels, agent for stabilizing blood vessels, and pharmaceutical composition | |
Ojokuku et al. | Evaluation of the chemical composition of Khaya grandifoliola and Ficus capensis | |
Bharti et al. | A review on medicinal plants having antioxidant potential | |
KR101901896B1 (en) | Shampoo composition for preventing hair loss comprising mixed ferment extracts of natural products | |
Prakash et al. | Gentiana lutea Linn.(yellow gentian): a comprehensive | |
KR101986186B1 (en) | Cpmposition for care of dermatic disease comprinsing plant extract | |
KR101412500B1 (en) | Cosmetic composition for improving atopic skin comprising herb extract fermented in bamboo cylinder and manufacturing method thereof | |
Shi et al. | The genus Orobanche as food and medicine: An ethnopharmacological review | |
KR20070056207A (en) | Testosterone 5alpha-reductase inhibitor containing vitis radix extract | |
CN107669565A (en) | A kind of natural antibacterial bath foam containing radix glycyrrhizae | |
KR20160019190A (en) | Composition comprising fermented ginseng or red ginseng extract containing increased ginsenoside Rd for improving atopic dematitis | |
KR102642582B1 (en) | cosmetic composition having anti-oxidant, anti-inflammatory and anti-allergy effects which comprise mixed extract of Common camellia flower, mugwort, Lingzhi mushroom | |
KR101981678B1 (en) | Complex antioxidant extract and cosmetic composition for promoting hair growth and improving scalp and hair | |
KR20200025245A (en) | Preparation for improving blood circulation comprising mixed oriental medicinal extracts | |
Thayyil et al. | Comparative Evaluation of in vitro antioxidant activities of various extracts from Chomelia asiatica (Linn) and Pavetta indica (Linn) | |
Al Hilfi et al. | Chemical composition and antioxidant activity of Ficus elastica Roxb. ex Hornem and Raphanus sativus L. selective dry extracts with potential antidiabetic activity | |
KR102004323B1 (en) | Cpmposition for care of scalp disease comprinsing plant extract | |
KR20160118417A (en) | Manufacturing Method and Composion for Viper Venom Liquid Mixture | |
Putra et al. | Benefits total phenolic and flavonoid content of Portulaca oleracea as Antioxidant and Antidiabetic: A Review | |
KR100603122B1 (en) | Compositions of herbal extracts and pharmaceutical compositions for preventing loss of hair and promoting growth of hair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
FPAY | Annual fee payment |
Payment date: 20161226 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180130 Year of fee payment: 5 |